Last update 25 Nov 2024
CorrectSequence Therapeutics Co., Ltd.

CorrectSequence Therapeutics Co., Ltd.

Private Company|
2020|
Shanghai Shi, China
|

Overview

Basic Info

Introduction
CorrectSequence Therapeutics (Correctseq) was established in August 2020 and is located in Shanghai, China. The company was founded by a team of four individuals, including Dr. Jia Chen and Dr. Bei Yang, professors at the School of Life Science and Technology at ShanghaiTech University, Dr. Li Yang, a researcher at the Biomedical Research Institute of Fudan University, and Dr. Hao Yin, a researcher at the Medical Research Institute of Wuhan University. The company aims to utilize innovative foundational editing technologies to assist critically ill patients, with the goal of discovering, developing, manufacturing, and commercializing gene therapies for various diseases. The company has developed multiple therapies based on a novel base editing system, which may offer potential safety and efficiency advantages compared to traditional gene editing approaches.

Tags

Infectious Diseases
Congenital Disorders
Hemic and Lymphatic Diseases
Gene therapy
Transformer Base Editor
Gene editing

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Gene therapy5
Transformer Base Editor1
Gene editing1

Corporation Tree

Boost your research with our corporation tree data.
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
2
4
Preclinical
Phase 1
1
2
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
CS-101
( BCL11A )
Beta-Thalassemia
More
Phase 1
CS-102
Neoplasms
More
Preclinical
CS-104
Genetic Diseases, Inborn
More
Preclinical
CS-103
Metabolic Diseases
More
Preclinical
CS-107
Infectious Diseases
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free